PYRATINE-6™ (PRK 124)

The first in Senetek’s second generation cytokinin pipeline to complete development, Pyratine-6™, has demonstrated superior results as compared to highly successful predecessor compounds in clinical testing.  Pyratine-6™  launched in the North American physician market in early 2008.  For more information about Pyratine-6™, please visit www.pyratine-6.com.

An independent comparative analysis evaluated the effectiveness of Senetek’s second-generation patented cytokinin, Pyratine-6™ relative to its original and highly successful anti-aging active ingredient, Kinetin. The analysis compared results of separate clinical studies conducted at the University of California, Irvine (Kinetin) and at the independent research laboratory RCTS, Inc. in Irving, Texas (Pyratine-6™). The subjects in the Pyratine-6™ clinical trial scored significantly higher on each measure than those in the Kinetin study throughout the 12 weeks of evaluation. In some measures the comparison was particularly notable, such as fine wrinkles (22% improvement with Pyratine-6™ vs. 2% improvement with Kinetin after eight weeks), skin roughness (86% improvement with Pyratine-6™ vs. 35% improvement with Kinetin after eight weeks) and overall skin aging (24% vs. 3% after eight weeks).  Click here to view clinical photos.

The Pyratine-6™ study also featured additional evaluative methodologies not included in the Kinetin study, such as the NOVA Dermal Phase Meter for measuring the skin's moisture content, and expert evaluations of reductions in erythema (redness) and acne lesions. The NOVA apparatus measured increases in skin moisture content of 35% and 41% after eight and twelve weeks, respectively. The evaluations found 42% and 62% reductions in erythema after two and four weeks, respectively, and a 45% reduction in acne lesions after twelve weeks. Pyratine-6™ was well tolerated by all subjects, producing no measurable skin irritation or signs of allergic contact dermatitis with twice-daily application over the 12 week study period.

Based on positive results demonstrated in these clinical evaluations, Senetek has initiated another clinical trial of Pyratine-6™ for the treatment of acne rosacea, a chronic dermatosis afflicting more than 45 million people worldwide.  Data suggests that Pyratine-6™ may offer important advantages over currently available treatments, primarily oral and topical antibiotics, which involve long-term tolerability and other health concerns.  Click here to view clinical photos.

For more information about Pyratine-6™, please visit www.pyratine-6.com.